Ajanta Pharma Financial Statements

Ajanta Pharma (AJANTPHARM) reported revenue of ₹47.43B in FY2025 with net income of ₹9.20B. Total assets stood at ₹50.15B and free cash flow was ₹8.39B.

Ajanta Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		29.16B	34.57B	38.41B	42.93B	47.43B
Cost of Rev. Cost of Revenue		-6.45B	-8.32B	-10.50B	-10.67B	-10.71B
Gross Profit		22.71B	26.24B	27.91B	32.27B	36.72B
SGA Sales, General & Admin		-12.46B	-15.79B	-19.09B	-19.70B	-23.18B
Op. Income Operating Income		9.08B	9.20B	7.51B	11.21B	12.10B
PBT Profit Before Tax		9.00B	9.09B	7.45B	11.14B	11.89B
Net Income		6.54B	7.13B	5.88B	8.16B	9.20B
Dil. Shares Diluted Shares		130.62M	129.66M	128.12M	126.01M	125.17M
Diluted EPS		50.06	54.97	45.89	64.77	73.53

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Ajanta Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Ajanta Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		20.28B	22.64B	28.25B	27.31B	28.43B
Non-curr. assets Total non-current assets		17.51B	17.91B	18.54B	19.07B	21.72B
Total assets		37.79B	40.56B	46.79B	46.38B	50.15B
Curr. liabilities Total current liabilities		6.49B	6.47B	11.39B	8.96B	9.96B
Non-curr. liab. Total non-current liabilities		1.34B	1.44B	1.52B	1.75B	2.29B
Total liabilities		7.83B	7.91B	12.91B	10.71B	12.25B
Total equity		29.96B	32.64B	33.88B	35.67B	37.90B
Total liab. & eq. Total liabilities & equity		37.79B	40.56B	46.79B	46.38B	50.15B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Ajanta Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Ajanta Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		9.00B	9.09B	7.45B	11.14B	11.89B
Operating CF Cash flow Operating Activities		5.76B	5.62B	7.92B	7.85B	11.57B
Capex Investments in PPE		-1.72B	-1.49B	-1.74B	-1.52B	-3.18B
Investing CF Cash flow Investing Activities		-2.82B	-741.00M	-5.60B	653.90M	-3.77B
Dividend Paid		-829.00M	-822.10M	-896.90M	-6.42B	-3.49B
Financing CF Cash flow Financing Activities		-3.18B	-4.60B	-1.08B	-10.51B	-7.33B
Cash (start) Cash at beginning of period		2.02B	1.78B	2.06B	3.30B	1.29B
Cash (end) Cash at end of period		1.78B	2.06B	3.30B	1.29B	1.77B
FCF Free Cash Flow		4.05B	4.13B	6.17B	6.33B	8.39B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Ajanta Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025